« More "More Scientists" Debate |
| Watch Your Cell Assays »
June 18, 2012
What Compound Are You Trying to Patent, Again?
I sure hope that Sanofi doesn't really want to own these compounds in this recent patent filing. (Thanks to a reader at another company for sending this along!) But what are the odds of that, given that they went to all the trouble of filing on them?
The reason I say that is while the compounds are drawn correctly in the experimental section (the part that was done by the chemists), the description and the claims (which were done by the lawyers) have the wrong structure in them. Wrong, as in doesn't match the experimentals, and wrong as in doesn't exist, either. The patent is directed towards indolizine derivatives, but the drawings in the claims are not indolizines, but are rather some sort of charged species whose name I do not exactly have at the tip of my tongue. Not that they're drawn any charges on anything, naturally, even though all those nitrogens have four bonds on them.
Does this invalidate the patent? Probably not, although I am most certainly not a lawyer. The names, as written, still seem to be fine. Does this complicate efforts to defend the chemical matter? You'd have to think so. Does it make people at Sanofi look like they either don't know much chemistry, aren't paying much attention, or both? Absolutely.
+ TrackBacks (0) | Category: Patents and IP
POST A COMMENT
- RELATED ENTRIES
- The Other Shoe Drops at Ariad
- Exiting Two Therapeutic Areas
- Organizing Research
- Now Novartis-Emeryville?
- BMS Reshuffling
- The Seat of Learning, Indeed
- Compassionate Access: No Good Answer
- Novartis Closing Horsham